Guard Therapeutics phase 2 results published in leading scientific journal | Placera
Guard Therapeutics' phase 2 AKITA study with RMC-035, targeting kidney injury post-open-heart surgery, showed significant kidney-protective effects, published in eClinicalMedicine. The study's results support the ongoing phase 2b POINTER study and future phase 3 development.
Reference News
Guard Therapeutics phase 2 results published in leading scientific journal | Placera
Guard Therapeutics' phase 2 AKITA study with RMC-035, targeting kidney injury post-open-heart surgery, showed significant kidney-protective effects, published in eClinicalMedicine. The study's results support the ongoing phase 2b POINTER study and future phase 3 development.